Patents by Inventor Norio Akaike

Norio Akaike has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11813265
    Abstract: Problem: to provide an activator for activating intracellular ATP production. Solution: use of a pyridodipyrimidine compound represented by the following formula (II): wherein, R1 and R3 each represent a hydrogen atom, an alkyl group, a halogen-substituted alkyl group, a carboxy-substituted alkyl group, a phenyl group, a phenyl group substituted by one of a halogen atom, a lower alkyl group, or a lower alkoxy group, or a lower alkyl disubstituted phenyl group and R2 represents an alkyl group, a cycloalkyl group, a phenyl-substituted lower alkyl group, a phenyl group, a phenyl group substituted by one of a halogen atom, a lower alkyl group, or a lower alkoxy group, or a lower alkyl disubstituted phenyl group for activating intracellular ATP production, the use comprising introducing said pyridodipyrimidine compound to a human-derived neuron cells, wherein said pyridodipyrimidine compound is used as a coenzyme factor effective for activating intracellular ATP production.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: November 14, 2023
    Assignee: TERA STONE Co., Ltd
    Inventors: Tomohisa Nagamatsu, Norio Akaike
  • Patent number: 11806351
    Abstract: Problem: to provide an activator for activating intracellular ATP production. Solution: use of deazaflavino-testosterone compound represented by the following formula (III): wherein, R1 represents a hydrogen atom, an alkyl group, a halogen-substituted alkyl group, a carboxy-substituted alkyl group, a phenyl group, or a phenyl group substituted by one of a halogen atom, a lower alkyl group, or a lower alkoxy group and R2 represents an alkyl group, a cycloalkyl group, a phenyl-substituted lower alkyl group, a phenyl group, a phenyl group substituted by one of a halogen atom, a lower alkyl group, or a lower alkoxy group, or a lower alkyl disubstituted phenyl group for activating intracellular ATP production, the use comprising introducing said deazaflavino-testosterone compound to a human-derived neuron cells, wherein said deazaflavino-testosterone compound is used as a coenzyme factor effective for activating intracellular ATP production.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: November 7, 2023
    Assignee: TERA STONE Co., Ltd
    Inventors: Tomohisa Nagamatsu, Norio Akaike
  • Patent number: 11439644
    Abstract: Problem: to provide an activator for activating intracellular ATP production. Solution: use of a 5-deazaflavin compound represented by the following formula (I): (wherein, R1 represents a hydrogen atom, an alkyl group, a halogen-substituted alkyl group, a carboxy-substituted alkyl group, or a phenyl group, R2 represents an alkyl group, a cycloalkyl group, a phenyl-substituted lower alkyl group, a phenyl group, a phenyl group substituted by one of a halogen atom, a lower alkyl group, or a lower alkoxy group, or a lower alkyl disubstituted phenyl group, and R3 and R4 each represent a hydrogen atom, a lower alkyl group, a halogen atom, a hydroxyl group, a nitro group, a cyano group, a lower alkoxy group, a phenyl-substituted lower alkoxy, a lower alkylamino group, a phenyl-substituted lower alkylamino group, or a lower alkylsulfonyl group).
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: September 13, 2022
    Assignee: TERA STONE Co., Ltd
    Inventors: Tomohisa Nagamatsu, Norio Akaike
  • Publication number: 20220265661
    Abstract: Problem: to provide an activator for activating intracellular ATP production. Solution: use of a pyridodipyrimidine compound represented by the following formula (II): wherein, R1 and R3 each represent a hydrogen atom, an alkyl group, a halogen-substituted alkyl group, a carboxy-substituted alkyl group, a phenyl group, a phenyl group substituted by one of a halogen atom, a lower alkyl group, or a lower alkoxy group, or a lower alkyl disubstituted phenyl group and R2 represents an alkyl group, a cycloalkyl group, a phenyl-substituted lower alkyl group, a phenyl group, a phenyl group substituted by one of a halogen atom, a lower alkyl group, or a lower alkoxy group, or a lower alkyl disubstituted phenyl group for activating intracellular ATP production, the use comprising introducing said pyridodipyrimidine compound to a human-derived neuron cells, wherein said pyridodipyrimidine compound is used as a coenzyme factor effective for activating intracellular ATP production.
    Type: Application
    Filed: May 6, 2022
    Publication date: August 25, 2022
    Applicant: TERA STONE Co., Ltd
    Inventors: Tomohisa NAGAMATSU, Norio AKAIKE
  • Publication number: 20220265662
    Abstract: Problem: to provide an activator for activating intracellular ATP production. Solution: use of deazaflavino-testosterone compound represented by the following formula (III): wherein, R1 represents a hydrogen atom, an alkyl group, a halogen-substituted alkyl group, a carboxy-substituted alkyl group, a phenyl group, or a phenyl group substituted by one of a halogen atom, a lower alkyl group, or a lower alkoxy group and R2 represents an alkyl group, a cycloalkyl group, a phenyl-substituted lower alkyl group, a phenyl group, a phenyl group substituted by one of a halogen atom, a lower alkyl group, or a lower alkoxy group, or a lower alkyl disubstituted phenyl group for activating intracellular ATP production, the use comprising introducing said deazaflavino-testosterone compound to a human-derived neuron cells, wherein said deazaflavino-testosterone compound is used as a coenzyme factor effective for activating intracellular ATP production.
    Type: Application
    Filed: May 6, 2022
    Publication date: August 25, 2022
    Applicant: TERA STONE Co., Ltd
    Inventors: Tomohisa NAGAMATSU, Norio AKAIKE
  • Publication number: 20200246340
    Abstract: Problem: to provide an activator for activating intracellular ATP production. Solution: use of a 5-deazaflavin compound represented by the following formula (I): (wherein, R1 represents a hydrogen atom, an alkyl group, a halogen-substituted alkyl group, a carboxy-substituted alkyl group, or a phenyl group, R2 represents an alkyl group, a cycloalkyl group, a phenyl-substituted lower alkyl group, a phenyl group, a phenyl group substituted by one of a halogen atom, a lower alkyl group, or a lower alkoxy group, or a lower alkyl disubstituted phenyl group, and R3 and R4 each represent a hydrogen atom, a lower alkyl group, a halogen atom, a hydroxyl group, a nitro group, a cyano group, a lower alkoxy group, a phenyl-substituted lower alkoxy, a lower alkylamino group, a phenyl-substituted lower alkylamino group, or a lower alkylsulfonyl group).
    Type: Application
    Filed: February 4, 2019
    Publication date: August 6, 2020
    Applicant: TERA STONE Co., Ltd
    Inventors: Tomohisa NAGAMATSU, Norio AKAIKE
  • Patent number: 8569238
    Abstract: The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: October 29, 2013
    Assignees: The Chemo-Sero-Therapeutic Research Institute, Ginkyo Academy Kumamoto Health Science University, National University Corporation Kumamoto University
    Inventors: Shintaro Kamei, Asami Shindome, Takayoshi Hamamoto, Hiroaki Maeda, Masaki Hirashima, Sachio Okuda, Misako Umehashi, Sachie Ogawa, Megumi Imuta, Norio Akaike, Kazuo Takahama, Ryoko Wada
  • Publication number: 20130224179
    Abstract: The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.
    Type: Application
    Filed: March 18, 2013
    Publication date: August 29, 2013
    Inventors: SHINTARO KAMEI, ASAMI SHINDOME, TAKAYOSHI HAMAMOTO, HIROAKI MAEDA, MASAKI HIRASHIMA, SACHIO OKUDA, MISAKO UMEHASHI, SACHIE OGAWA, MEGUMI IMUTA, NORIO AKAIKE, KAZUO TAKAHAMA, RYOKO WADA
  • Publication number: 20120225818
    Abstract: The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.
    Type: Application
    Filed: August 5, 2010
    Publication date: September 6, 2012
    Applicants: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE, NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, GINKYO ACADEMY KUMAMOTO HEALTH SCIENCE UNIVERSITY
    Inventors: Shintaro Kamei, Asami Shindome, Takayoshi Hamamoto, Hiroaki Maeda, Masaki Hirashima, Sachio Okuda, Misako Umehashi, Sachie Ogawa, Megumi Imuta, Norio Akaike, Kazuo Takahama, Ryoko Wada
  • Patent number: 4128456
    Abstract: An electrical sensing and stimulation electrode small enough to record intracellular activity within a single living cell. The electrode incorporates a cylindrical chamber with a finely tapered end section. The chamber is evacuated to hold the cell at its tip. Contained within the chamber are piping, circuitry, and controls to provide selected life support environment, stimulation, and continuous sensing of the iternal ionic composition of the captured cell.
    Type: Grant
    Filed: October 11, 1977
    Date of Patent: December 5, 1978
    Inventors: Kai S. Lee, Norio Akaike, Arthur M. Brown